Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063503 | PMC |
| http://dx.doi.org/10.25259/Cytojournal_23_2020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CBC With Differential and Cell Population Data in Prediction of Fever With Thrombocytopenia Syndrome.
Int J Lab Hematol
December 2024
The First Affiliated Hospital With Nanjing Medical University, Nanjing, People's Republic of China.
Introduction: We aimed to identify additional predictors of severe fever with thrombocytopenia syndrome (SFTS), which has a significantly increasing global incidence.
Methods: This retrospective study included 95 patients with SFTS and 30 healthy individuals. Complete blood count with differential was performed using Sysmex XN 9000 and Mindray BC-6800 Plus analyzers.
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Clin Pathol
December 2024
Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive neoplastic process of precursor plasmacytoid dendritic cells. The diagnostic evaluation of this heterogenous entity is challenging, requiring a comprehensive approach of incorporating clinical, morphologic, immunohistochemical, and molecular/cytogenetic evaluations. Optimal management of BPDCN remains controversial, and clinical outcomes continues to be poor.
View Article and Find Full Text PDFThe role of ATP6V0D2 in breast cancer: associations with prognosis, immune characteristics, and TNBC progression.
Front Oncol
November 2024
Department of Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Objective: Researches have identified ATPase H+ transporting V0 subunit d2 (ATP6V0D2) as a significant factor in various cancers. However, its prognostic value in breast cancer (BRCA) and its biological role in BRCA cells remain unclear.
Methods: In this research, we examined the varying expression levels of ATP6V0D2 in both BRCA and normal breast tissue by utilizing information derived from databases including the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), along with clinical samples.
CAR-T cell therapy : recent updates and challenges in autoimmune diseases.
J Allergy Clin Immunol
December 2024
Univ. Franche-Comté, INSERM, EFS BFC, UMR1098,25000 Besançon France; CHU Besançon, Service de Dermatologie, 25000 Besançon, France.
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, demonstrating significant clinical efficacy and leading to FDA approval of several CAR-T cell-based products. This success has prompted exploration of CAR-T cell therapy in other disease areas, including autoimmune diseases (AIDs). CAR-T cells targeting B cells have been shown to provide clinical and biological improvements in patients with refractory AIDs.
View Article and Find Full Text PDFMechanosensing regulates pDC activation in the skin through NRF2 activation.
J Exp Med
March 2025
HSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery, New York, NY, USA.
Plasmacytoid DCs (pDCs) infiltrate the skin, chronically produce type I interferon (IFN-I), and promote skin lesions and fibrosis in autoimmune patients. However, what controls their activation in the skin is unknown. Here, we report that increased stiffness inhibits the production of IFN-I by pDCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!